



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181
 Unaudited Financial Results for the Quarter ended 30.06.2014

PART-I Particulars	Rs. In lacs			
	3 months ended 30.06.2014 Unaudited	3 months ended 31.03.2014 Audited	3 months ended 30.06.2013 Unaudited	12 Months ended 31.03.2014 Audited
1 Income from operations				
a Net sales/Income from Operations (Net of excise duty)	3391.31	3128.08	3807.88	14385.09
b Other Operating Income				
Total Income from operations (net)	3391.31	3128.08	3807.88	14385.09
2 Expenses				
a Cost of materials consumed	861.62	1047.14	2002.68	5461.64
b Purchases of stock-in-trade	209.63	565.48	147.09	1294.90
c. Changes in inventories of finished goods, work in	464.84	-939.18	-33.59	-285.94
d. Employee benefits expenses	894.98	1022.02	874.89	3783.43
e. Depreciation and amortisation expense	71.09	68.51	69.11	282.54
f. Other expenses	670.67	1061.74	611.86	3063.27
Total expenses	3172.83	2825.71	3672.04	13599.84
3 Profit from Operations before Other Income, Finance				
Cost and Exceptional items (1-2)	218.48	302.37	135.84	785.25
4 Other Income	3.11	6.07		6.07
5 Profit from ordinary activities before finance cost and	221.59	308.44	135.84	791.32
Exceptional items (3+4)				
6 Finance Cost	120.61	183.16	134.98	538.19
7 Profit from ordinary activities after finance cost but	100.98	125.28	0.86	253.13
before Exceptional Items (5-6)				
8 Exceptional items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax	100.98	125.28	0.86	253.13
(7+8)				
10 Tax expense	30.00	3.08	0.50	41.06
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-	70.98	122.20	0.36	212.07
10)				
12 Extraordinary Items (net of tax expense Rs. lacs)				
13 Net Profit(+)/Loss(-) for the period(11-12)	70.98	122.20	0.36	212.07
14 Share of profit/(Loss) of associates				
15 Minority interest				
16 Net Profit/(Loss) after taxes, minority interest and share	70.98	122.20	0.36	212.07
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance				7298.31
sheet of dr. Accounting vt				
19.i Earnings Per Share (before extraordinary items)				
a. Basic (Rs.)	0.27	0.47	0.00	0.81
b. Diluted (Rs.)	0.27	0.47	0.00	0.81
19.ii Earnings Per Share (after extraordinary items)				
a. Basic (Rs.)	0.27	0.47	0.00	0.81
b. Diluted (Rs.)	0.27	0.47	0.00	0.81
PART-II				
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
2 Promoter and promoter group shareholding				
a. Pledged / encumbered				
- Number of shares				
- Percentage of shares (as a % of the total shareholding				
of Promoter and promoter group)				
- Percentage of shares (as a % of the total share capital				
of the Company)				
b. Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding	100%	100%	100%	100%
of Promoter and promoter group)				
- Percentage of shares (as a % of the total share capital	65.79%	65.79%	65.79%	65.79%
of the Company)				
B INVESTOR COMPLAINTS				
Pending at the beginning of the quarter	0			
Received during the quarter	40			
Disposed of during the quarter	40			
Remaining unresolved at the end of the quarter	0			

Notes

- The Unaudited Financial Results for the Quarter ended 30.06.2014 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its adjourned meeting held on 21.08.2014
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.

By Order of the Board
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
 Managing Director

Place : New Delhi
 Date : 21.08.2014



LIMITED REVIEW REPORT FOR JAGSONPAL PHARMACEUTICALS LIMITED
TO WHOM IT MAY CONCERN

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.06.2014, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO.,
Chartered Accountants



Place : New Delhi
Date : 21.08.2014


SURESH SETHI
PARTNER
F.R. No. 000632 N
Membership no. 89318